Another Promising Study

Options

Comments

  • JohnSmith
    JohnSmith Member Posts: 651
    edited August 2016

    Interesting, despite being very "pre-clinical" (They have not moved beyond petri dish models).
    This approach falls under the umbrella of Immunotherapy and the study targeted HER2+ breast cancer cells with a antibody–sialidase conjugate (combining Herceptin and recombinant sialidase) which activated more efficient anti-tumor killing via NK cells and Macrophages.

    Long way to go to human trials...

Categories